스타틴 치료 시 부작용에 대한 전략

키워드

참고문헌 (21)

1. 한국보건사회연구원, "한국인의 주요 상병 및 건강행태 분석: 2001년 국민 건강, 영양조사 건강 부문 심층 분석 결과." (2003), 보건복지부.
2. "Expert panel on detection and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program expert panel on detection and treatment of high blood cholesterol in adults(Adult Treatment Panel III).", 285, pp.2486~2497 (2001)
3. "Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report.", 106, pp.3143~3421 (2002)
4. Blasetto JW,, "Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.", 91, pp.3C~10C (2003)
5. Stamler J, "Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded Findings in 356 222 primary screens of the Multiple Risk Factor Intervention Trial", pp.2823~8
6. Shepherd J, "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.", 333, pp.1301~1307 (1995)
7. Downs JR, "Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS", TexCAPS., 1998, pp.279, 1615~1622
8. the Scandinavian Simvastatin Survival Study, "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease", pp.1383~9
9. Sacks FM, "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.", 335, pp.1001~1009 (1996)
10. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, "Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.", 339, pp.1349~1357 (1998)
11. Athyros VG,, "Treatment with atorvastatin to the National Cholesterol Education Program Goals versus ‘usual’ care in secondary coronary heart disease prevention: The Greek Atorvastatin and Coronary-heart- disease Evaluation (GREACE) study.", 18, pp.220~228 (2002)
12. Heart Protection Study Collaborative Group, "MRC", BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial., 2002, pp.360, 7~
13. Goldberg RB, "for the CARE Investigators. Cardiovascular event and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the Cholesterol And Recurrent Events (CARE) trial.", 98, pp.2513~2519 (1998)
14. Heart Protection Study Collaborative Group, "MRC", BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial., 2003, pp.361, 2005~2016
15. Shepherd J, "Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.", 360, pp.1623~1630 (2002)
16. Primatesta P,, "Lipid concentrations and the use of lipid lowering drugs evidence from a national cross sectional survey.", 321, pp.322~325 (2000)
17. Hanfeld M, "Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor.", 55, pp.399~405 (2001)
18. Luther TC, "Treating dyslipidemia with statins: The risk-benefit profile.", 145, pp.387~396 (2003)
19. Shelina MJ,, "Rhabdomyolysis associated with hyeroxymethylglutaryl-coenzyme A reductase inhibitors.", 147, pp.956~965 (2004)
20. Worz CR,, "The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.", 2, pp.1119~1127 (2001)
21. Hanston PD,, "Drug interactions with HMG-CoA reductase inhibitors.", 2, pp.103~106 (1998)

관련 논문AI추천